Next-generation HIV prevention pill, which has fewer toxic side effects than Gilead’s inferior prior drug, Truvada, was approved by the FDA Thursday for use as pre-exposure prophylaxis.
Both drugs cost about $1,800 a month per patient. AHF cites the billions of dollars Gilead has already made on its roster of HIV/AIDS drugs as well as its willful promotion and sales of Truvada, the more toxic earlier form of the drug, (tenofovir disoproxil fumarate) that causes permanent kidney and bone damage.